Forensic Analysis · Medical Devices · as of Nov 7, 2026
3M Co (MMM)
A forensic read on 3M Co built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
Safe
Financial health
5.5
Distress distance
4
Forensic signals
76.1%
ROE
1.5%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
3M Co earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 5.5, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by shareholder returns.
What the filings flag
345% of FCF
FY2025
Shareholder returns.Returned $4.8B to shareholders (buybacks + dividends) in FY2025 — 345% of free cash flow. That is $3.4B (245%) more than free cash flow covered, and more than operating cash flow as well. It came out of the balance sheet's own liquid holdings, not new debt: cash fell $365M over FY2025, while total debt fell $442M — $365M of the $3.4B. The FY2025 cash-flow statement filed $3.5B from sales and maturities of investments against $1.3B of investments purchased; $95M from sales of property and equipment; net cash provided by investing activities of $1.4B; net cash used in financing activities of $4.0B. A payout past free cash flow draws the balance sheet down in every year it continues, which isn't sustainable indefinitely. Counting the $225M of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 361%.
52d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 47 to 52 days FY2024→FY2025 (receivables +11% vs revenue +2%). Receivables are creeping up relative to sales. Across FY2023–FY2025 the day count ran 53 → 47 → 52 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in. Both figures are measured on period-end balances rather than the beginning-plus-ending average, because averaging needs the balance a year before every reading — FY2024's opening balance is on file, but across the 3 fiscal years read here (FY2023–FY2025) the average yields only 2 day counts (1 step), too few to tell a climb from one year's move.DSO (days sales outstanding): the average days the company waits to collect cash after a sale.
14.2%
FY2025
Return on invested capital.Return on invested capital is 14.2% in the latest fiscal year and rising across FY2023–FY2025 from -27.7%. After-tax operating profit was ($8.4B) in FY2023 and $3.5B in FY2025, with operating income at -43.4% of revenue in FY2023, 19.6% in FY2024 and 18.6% in FY2025. The capital base behind it came down -19% across FY2023–FY2025, from $30.5B to $24.8B, so this return is struck on a smaller base than it started on.
-40%
FY2023→FY2024
Dividend — cut.The payout was CUT ~40% in FY2024 (from FY2023). It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies.
Key fundamentals
Latest Revenue$24.95B
Revenue Growth YoY+1.5%
Revenue CAGR (2yr)+0.7%
Net Margin13.0%
Free Cash Flow$1.40B
Return on Equity76.1%
Debt / Equity2.68x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from 3M Co's actual 10-K/10-Q/8-K filings?